Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why

Takeda on Friday notified Denali Therapeutics regarding the termination of their collaboration agreement to co-develop DNL593, a progranulin replacement therapy for frontotemporal dementia.